Blakley Flashcards
How are organochlorines absorbed
Well absorbed through skin and MM
Poorly absorbed through lungs and GIT
Distribution of organochlorines
Accumulate in lipid tissues; Readily detectable in liver, kidney brain and fetus
metabolism of organochlorines
dechlorinated slowly in the liver; many metabolites are highly toxic
how are organochlorines excreted
through the bile; enterohepatic recycling occurs
what is organochlorines mechanism of action
K efflux is hindered and Na depolarization is prolonged –> decreasing transmembrane resting potential (decreased firing threshold)
other mechanisms of action for organochlorines
increased synaptic activity, increased neurotransmitter release from presynaptic terminals and inhibition of GABA
what is the susceptibility of cats to organochlorines
5 times more susceptible than most species
what are the clinical manifestations of organchlorines
behavioral abberations (anciety, apprehension, head between legs, licking excessively), nervous phenomena (hypersensitivity, muscle twitching, jaw clamping, clonic tonic convulsions, opisthotonus), autonomic manifestations (minimal but do occur – salivation, diarrhea, dyspnea), locomotor disturbance (stiff gait, ataxia, incoordination)
PM findings with organochlorines
non-specific; GIT (hemorrhage and congestion), mild fatty degeneration of liver and kidney, degenerative changes in thyroid, pancreas, testis and adrenal glands
Treatment of organochlorines
Wash off skin, gastric lavage, activated charcoal, mineral oil (to force through and bind), sedation, IV lipid emulsion
residue concerns of organochlorines
milk and meat residues are a major concern due to reproductive, carcinogenic and immunosuppresive effects
diagnosis of organochlorines
analyze fat, milk, liver, kidney and GI contents
3 major groups of anticholinesterase compounds
organophosphates insecticides, carbamate insecticides and nicotinoid insecticides
residue concerns with anticholinesterase compounds
not a concern because rapidly degraded with short half life
absorption of anticholinesterase compounds
well absorbed by all routes including dermal and respiratory
distribution of anticholinesterase compounds
rapidly to all tissues; no accumulation in fat
excretion of anticholinesterase compounds
excreted rapidly in a few days
mechanism of action of anticholinesterase compounds
inhibition of acetylcholinesterase prevents break down of acetylcholine
enzymes affected by anticholinesterase compounds
pseudo(plasma) cholinesterase (non-specific) and true (RBC) cholinesterase (80%)
specific mechanism of action of organophosphate
forms a stable enzyme-organophosphate complex that is practically irreversible
specific mechanism of action of carbamates
carbamate enzyme complex is not as stable so enzyme inhibition is reversible
nicitinoid compound mechanism of action
binds to nicotinic receptors therefore no inhibition of acetylcholinesterase BUT need extreme high doses to bind a sufficient number of receptors to cause signs
clinical manifestations of anticholinesterase compounds
excessive muscarinic and nicotinic stimulation starting 5 minutes to 1-2 hours after exposure; diarrhea, vomiting, salivation, dyspnea due to bronchoconstriction, decreased HR, pupil constriction
with what anticholinesterase compound does delayed neurotoxicity occur with
organophosphates
clinical signs of delayed neurotoxicity (organophosphates)
develops 10D to 3M after exposure; irreversible effects of muscle weakness especially in hind limbs, knuckling, ataxia (flaccid paralysis), cats unable to retract claws, normal acetylcholinesterase
PM findings of delayed neurotoxicity (organophosphates)
axonal degeneration, peripheral neuropathy, degeneration of myelin sheath
diagnosis of delayed neurotoxicity (organophosphates)
histo exam of spinal cord, chemical analysis of tissues and history of previous exposure
PM findings for anticholinesterase compounds
few lesions, petechial hemorrhage and congestion on viscera, slight pulmonary edema
Diagnosis of anticholinesterase compounds
history, cholinesterase activity in heparinized blood (measured by Michel’s change in pH for organophosphates only or titrimetric pH stat for carbamates/organophosphates
factors that influence the measurement of cholinesterase activity
aging, enzyme denaturation, spontaneous reaction (carbamate)
treatment of anticholinesterase toxicity
atropine (non-competitive antagonist that blocks muscarinic receptors), 2-PAM (for organophosphates only, contraindicated in carbamates), wash, activated charcoal, bicarb and fluids
mechanisms of action of lead
based on the affinity of lead for SH or imidazole groups; binds to various macromolecules to impair their function
(enzymes, decreases cellular respiration and ATP production due to effect on mitochondria, embryotoxic, teratogenic, immunosuppression)
absorption of lead
1-2% in adults, 30-40% in young
distribution of lead
cumulative toxin; distributes to liver and kidney within the day, chronic exposure displaces Ca in bone (does NOT go to brain)
excretion of lead
kidney and minor excretion in milk
effect of lead on the GIT
irritation and gastroenteritis
effect of lead on nervous system
encephalopathy – capillary damage causes hemorrhage and congestion in the brain followed by edema and malacia +/- blindness and peripheral nerve damage
effect of lead on hemopoetic system
anemia associated with decreased iron uptake, increased RBC fragility, and impaired heme synthesis; can see basophilic stippling
effect of lead on kidney
degenerative changes – tubular necrosis, nephritis, fibrosis and hyaline degeneration (acid fast inclusion bodies)
effect of lead on respiratory system
swallowing mechanisms can be impaired by neuro dysfunction leading to aspiration pneumonia
duration of acute lead poisoning
short; typically less than 24 hours
clinical manifestations of acute lead poisoning (cattle)
behavioral changes (mania, bellowing, head pressing), locomotor disturbances (staggering and muscle tremors), nervous phenomena (clamping jaws, blindness, hyperaesthesia, intermittent tonic-clonic convulsions, opisthotonus), GIT (rumen stasis, salivation, abdominal pain)
clinical manifestation of subacute lead poisoning (cattle)
dullness and head pressing, variable locomotor disturbances, blindness, depression, hyperaesthesia, NO CONVULSIONS, grinding teeth, anorexia
lead poisoning in sheep
usually subacute and may have osteoporosis
lead poisoning in horses
usually chronic – colic, diarrhea, pharyngeal paralysis, aspiration pneumonia, inspiratory dyspnea, roaring
lead poisoning in swine
primarily GI signs, vomiting, few CNS signs
lead poisoning in dogs
anorexia, vomiting, colic, hyperexcitability, convulsions, hysterical bark
diagnosis of lead poisoning
lead analysis of liver and kidney
antemortem diagnosis of lead poisoning
heparinized blood, rumen contents, fecal contents
clinical pathology of lead poisoning
anemia, basophilic stipling, increased ESR, hypochromia, leptocytes, proteinuria, glucosuria
treatment of lead poisoning
chelation therapy (penicillamine, BAL, Ca EDTA)
supportive care of lead poisoned animals
force feeding, oral fluids, mannitol
residue concerns of lead poisoning
treatment of food animals is not recommended due to meat and milk residues
lead half life
many months
3 forms of mercury
elemental metal mercury, inorganic mercury, organic mercury
absorption of metal mercury
well absorbed by inhalation
inorganic mercury absorption
poor; burns skin
absorption of inorganic mercury
well absorbed by skin and GIT (lipophilic)
metabolism of mercury
converted to inorganic forms but in environment be converted to organic mercury (methyl mercury)
distribution of mercury
liver and kidney accumulate high quantities; fetus acts as a sink and protects mother)
excretion of inorganic mercury
urinary
excretion of organic mercury
bile and feces; 70D half life
mechanism of action of inorganic mercury
causes corrosive damage and tissue necrosis (irritation); binds with sulfhydryl groups causing reduced metabolic activity and degenerative change)
mechanism of action of organic mercury
interferes with metabolic activity causing degenerative changes
clinical manifestation of inorganic mercury
GIT and neurological syndrome; anorexia, vomiting, salivation, diarrhea, stomatitis, ulcers, ataxia, tremors, terminal convulsions, depression, paresis, hematuria, proteinuria, uremia, epistaxis, dyspnea, (alopecia and keratinization occur with chronic)
clinical manifestations of organic mercury
ataxia, tremors, terminal convulsions, depression, paresis, hematuria, proteinuria, uremia, epistaxis, dyspnea, (alopecia and keratinization occur with chronic)
PM of inorganic mercury
gastroenteritis, stomatitis, mucosal hemorrhage and edema, ulcers, interstitial nephritis, tubular necrosis, edema, bronchitis, hydrothorax, mild liver necrosis, encephalomalacia, cerebellar atrophy of offspring
PM of organic mercury
interstitial nephritis, tubular necrosis, edema, bronchitis, hydrothorax, mild liver necrosis, encephalomalacia, cerebellar atrophy of offspring
diagnosis of mercury
clinical manifestations and pathology of CNS and GIT; analysis of blood, liver or kidney for mercury
treatment of mercury
success is limited by long half life and degenerative organ change; sodium thiosulfate, egg whites, milk, astringents; chelators such as BAL are used to treat pets
residue concerns of mercury
major concerns due to milk and meat residues being lengthy and highly teratogenic nature
forms of arsenic
organic (less toxic, CNS) and inorganic (severe GI signs and CNS)
arsenic absorption
readily absorbed through skin or GIT
arsenic distribution
accumulates in energy rich tissues (liver, kidney, GI epithelium); with chronic exposure will be in hair and hoof as well
excretion of arsenic
bile or urine
arsenic mechanism of action
metabolic poison that impairs cellular respiration and uncouples oxidative phosphorylation (degenerative changes)
mechanism of action of inorganic arsenic
chemical irritation, tissue degeneration and metabolic poison
clinical manifestation of acute inorganic arsenic
high mortality, sudden onset, vomiting, abdominal pain, weakness, ataxia, recumbency, shock, diarrhea and death within 3-4 hours
clinical manifestations of subacute inorganic arsenic
duration of 2-7 days with more neuro signs; colic, vomiting, diarrhea, salivation, grinding teeth, dehydration and shock, muscle tremors, incoordination, clonic convulsions, hind end paralysis
clinical manifestations of chronic inorganic arsenic
vague, unthrifty animals with poor growth, indigestion, reduced milk production, abortion and buccal cavity ulceration
diagnosis of inorganic arsenic
clinical signs, analysis of liver, kidney, hair, or food
arsenic half life
only a few days
treatment of inorganic arsenic poisoning
BAL is first choice because will pull out of brain; sodium thiosulfate (sulfur binds arsenic), fluid therapy is essential for shock
types of organic arsenic used as feed additives
arsanilic acid (least toxic), roxarsone, nitrophenylarsonic acid (5x more toxic than arsanilic)
elimination rate of organic arsenic
rapidly eliminated – short withdrawal times
clinical manifestation of acute organic arsenic
symptoms in about 1 week, incoordination, ataxia, paralysis, blindness, not anorexia and no GI signs (CONSUME FOOD UNTIL LATE STAGES)
clinical manifestations of chronic organic arsenic
similar signs to acute but to a lesser extent